Skip to main content
Clinical Trials/NCT05927714
NCT05927714
Completed
Not Applicable

Palatal Donor Site Wound Healing Following Periodontal Plastic Surgery Using Amnion-Chorion Membrane: Site- and Patient-Centered Outcomes

The University of Texas Health Science Center at San Antonio1 site in 1 country74 target enrollmentSeptember 11, 2023
ConditionsPalate; Wound

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Palate; Wound
Sponsor
The University of Texas Health Science Center at San Antonio
Enrollment
74
Locations
1
Primary Endpoint
Wound healing time
Status
Completed
Last Updated
last year

Overview

Brief Summary

The purpose of this clinical trial is to assess if donor site healing in the palatal area and patient pain perception are similar or different when using amnio-chorion membrane (ACM) on the donor site after surgery compared to a commonly used commercial hemostatic agent (ActCel Cellulose Gauze).

Detailed Description

Resorbable oxidized cellulose materials are commonly used as hemostatic agents in medicine and dentistry. Surgicel and ActCel are used daily in surgical practice. When these products come in contact with blood, they convert to a gel that expands to cause direct pressure on blood vessels and control bleeding. ActCel is water-soluble and dissolves over a short time period. It can be removed easily when water, saline or hydrogen peroxide is applied.The study team will examine the effects of ACM as a wound dressing for the donor area and compare the rate of epithelialization with and without its use.

Registry
clinicaltrials.gov
Start Date
September 11, 2023
End Date
April 3, 2025
Last Updated
last year
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • Patients between age 18 and 89
  • Patients needing an FSTA in the area of the mouth from 2nd molar to 2nd molar in the maxilla or mandible at sites that have teeth or implants, or in sites that are edentulous
  • Patients must be nonsmokers, former smokers, or current smokers who smoke \<10 cigarettes per day, by self-report
  • Female patients who have undergone a hysterectomy, tubal ligation, or menopause, and non- pregnant women of child-bearing potential.
  • Must have access to Smartphone

Exclusion Criteria

  • Patients who disclose that they will not be able to cooperate with the follow-up schedule.
  • Patients who are mentally incompetent, prisoners, or pregnant (as obtained via chart review or self-report)
  • Pregnant women or women intending to become pregnant during study period
  • Smokers who smoke \> 10 cigarettes per day

Outcomes

Primary Outcomes

Wound healing time

Time Frame: 1, 2, 3 and 4 weeks post-operatively

Change in Area of wound epithelialization will be measured in mm2 at 1, 2, 3 and 4 weeks postoperatively using an Early wound healing index (EHI) index. The index assesses 5 dichotomous variables, each with a "yes" or "no" assessment. "Yes" = score of 1; "No" = score of 2. Total score can range from 5 minimum to 10 maximum. The 5 variables are: * bleeding on palpation? * incomplete epithelialization? * presence of redness? * presence of swelling? * granulation tissue present?

Post-operative pain

Time Frame: 24, 48 and 72 hours post-surgery

Change in pain will be assessed post surgery using a smart-phone application that captures the pain level in a scale of 1-10, where a lower number indicates a less pain

Study Sites (1)

Loading locations...

Similar Trials